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ABSTRACT
A small fraction of patients with asthma have
severe, persistent disease that is often refractory
to standard therapy. To meet this need, a
growing emphasis has been placed on the
development of alternative, novel therapies
and the ability to characterize those patients
who are most likely to benefit from these
therapies. The eosinophil has been identified
as a primary mediator in airway inflammation
and as a potential pharmacological target. This
narrative review outlines the need for more
phenotype-directed therapies in severe asthma,
and discusses the supporting evidence for
monoclonal antibodies directed against key
pro-eosinophilic T-helper 2 (Th2)
inflammatory cytokines as additive agents in
the treatment of severe asthma with an
eosinophilic phenotype.
Keywords: Biologic therapy; Eosinophils;
Severe asthma
INTRODUCTION
Asthma affects 25.7 million people worldwide,
and is associated with a significant healthcare
and economic burden to patients and society
[1]. Three to ten percent of adults diagnosed
with asthma are believed to suffer from severe,
refractory disease [2, 3]. A single exacerbation
requiring urgent intervention can increase the
annual treatment costs by as much as threefold
[4], and recurrent exacerbations have been
shown to result in a progressive loss of lung
function in some patients [5]. Up to 30% of
adults with severe asthma will require oral
corticosteroids in addition to inhaled
corticosteroids to maintain control [6–8].
There is a need to identify those patients who
are most at risk for exacerbations and to
characterize the potential treatment options
that might reduce these risks [9]. It has been
suggested that within this group of patients,
detailed phenotyping or characterizing based on
readily observable traits [10] using clinical
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symptoms, markers of inflammation, and lung
function might be useful [3, 9, 11]. Although
there is no widely agreed upon phenotypic
classification scheme, most proposed groupings
include an early-atopic or allergic group, a
delayed-onset group (often involving obese
patients with a female predominance), and a
late-onset, eosinophilic predominant group
[3, 10–12], as shown in Table 1. However, in
asthma, each phenotype does not necessarily
yield a distinct endotype or subgroup defined by
pathogenetic mechanisms of disease at a more
cellular level [10]. This consensus has shifted the
current research focus towards differentiating
the pathobiologic mechanisms of each group so
that targeted therapies can be developed.
Recurrent exacerbations are a major
contributor to asthma-related morbidity in






























































Asthma phenotypes are continually evolving as the relationships between biological characteristics and endotypes change.
This table includes examples of some of the most commonly accepted phenotypes
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many patients, and seem to predominate in a
subgroup with eosinophilic airway inflammation
[9, 13]. Although inhaled corticosteroids are
effective at reducing airway eosinophilia, up to
50% of patients with severe asthma will have
persistent eosinophilia despite treatment [14, 15],
suggesting that selective targeting of airway
eosinophilia may have benefit.
The purpose of this narrative review is to
illustrate both the importance of eosinophilic
inflammation in the airway as a distinct subtype
of severe asthma, and to review the biologic
therapies that are under investigation to
specifically treat this patient population. This
article is based on previously conducted studies
(see Table 2), and does not involve any new
studies of human or animal subjects performed
by any of the authors.
ROLE OF EOSINOPHILS
Eosinophils have been shown to promote
airway inflammation and remodeling in
asthma [16], and elevated peripheral blood
eosinophil counts have been identified as an
independent risk factor for asthma
exacerbations [17–20]. Additionally, a
reduction in sputum eosinophil count in those
patients with moderate to severe asthma has
been shown to reduce exacerbations [21–23]
and hospital admissions [21]. T-helper type 2
(Th2) lymphocytes are thought to play a key
role in the pathogenesis of asthma [24], with an
increased serum immunoglobulin E (IgE) and
elevated peripheral blood eosinophil count
defining the classic phenotype [25]. Blockade
of the key Th2 cytokines interleukins-4, -5, and
-13 (IL-4, IL-5, and IL-13) is a plausible target for
the development of biologic therapies for
patients with asthma who remain
uncontrolled on conventional therapies.
MEPOLIZUMAB
Interleukin-5 (IL-5) is a pro-inflammatory
cytokine released predominantly by helper T
cells that stimulates maturation [26] and
activation of eosinophils [27], making it a
logical target to reduce eosinophil-driven
inflammation. Mepolizumab is a humanized
monoclonal antibody against IL-5 that prevents
the binding of IL-5 to the receptor complex on
the surface of the eosinophil [28]. It selectively
inhibits eosinophilic inflammation [29–32] and
reduces the numbers of eosinophils in the blood
and sputum [31, 33–37]. In an early phase-two,
double-blinded, randomized,
placebo-controlled trial of adults with
moderately severe asthma with persistent
symptoms despite inhaled corticosteroid
therapy [33], Flood-Page and colleagues
evaluated the potential benefit of
mepolizumab as add-on therapy. While no
clinically significant benefit was noted in the
treatment arm, the study did demonstrate
safety of administration and a nonsignificant
trend towards reduced frequency of
exacerbations despite a short three-month
study period. Additionally, it confirmed
mepolizumab’s ability to markedly reduce
peripheral blood and sputum eosinophils,
raising the important question that perhaps
with more careful phenotyping, mepolizumab
would be more beneficial.
Subsequent clinical studies of mepolizumab
began to better elucidate the relevant
phenotype in which this agent might be
effective. In 2009, Haldar et al. compared
mepolizumab versus placebo in the treatment
of refractory eosinophilic asthma [34]. The
study population included 61 adult patients
who met the American Thoracic Society
definition of refractory asthma [38], evidence
of eosinophilic inflammation in sputum
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Table 2 Primary outcomes of randomized controlled trials
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Table 2 continued
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samples defined by a sputum eosinophil count
of 3% or greater at least once in the previous
two years despite high-dose (either inhaled or
systemic) corticosteroid therapy, and recurrent
exacerbations. Over the 50-week trial period,
there was a significant reduction in total
number and rate of exacerbations [relative risk,
0.57; 95% confidence interval (CI), 0.32–0.92;
p = 0.02], as well as a modest improvement in
the Asthma Quality of Life Questionnaire
(AQLQ) score (mean improvement in AQLQ
0.55 (minimal clinically important difference
0.5 [39])). However, there was no effect on
asthma symptoms or forced expiratory volume
in one second (FEV1), suggesting that these
markers of disease may be improved through
other mechanisms. The only serious adverse
events reported were hospitalizations for severe
asthma (10% mepolizumab vs. 34% placebo).
A follow-up report by the same authors 12
months after trial completion included the
majority (56 of 61) of subjects included in the
original study [40]. After cessation of
mepolizumab, participants experienced
significant increases in peripheral blood and
sputum eosinophil counts as soon as three
months after trial completion, followed by an
increase in exacerbation frequency and
worsening asthma control as noted by the
Juniper Asthma Control Questionnaire (JACQ).
The increase inbothperipheral blood and sputum
eosinophils preceding the increase in rate of
Table 2 continued
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AJRCM: American Journal of Respiratory and Critical Care Medicine, NEJM: The New England Journal of Medicine, AJEM:
American Journal of Emergency Medicine, ICS inhaled corticosteroid, ACQ asthma control questionnaire, LABA long-acting
beta agonist, AQLQ asthma quality of life questionnaire, JACQ Juniper asthma control questionnaire, FEV1 forced
expiratory volume in one second, FVC forced vital capacity, FEF25–75% forced expiratory ﬂow between 25% and 75% of
forced vital capacity, SABA short-acting beta agonist
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exacerbations suggests a relationship between
eosinophilic inflammation and asthma control.
In a similar cohort of patients, Nair et al.
showed an association between intravenous
mepolizumab administration and overall
reduction in daily prednisone dose [35] in a
smaller, proof of concept study. Twenty adult
patients who required daily treatment with oral
prednisone and high-dose inhaled
glucocorticoids (600–2000 lg of fluticasone or
equivalent) to control symptoms and had
persistent sputum eosinophilia with a least 3%
of cells in an induced sputum sample were
randomized to either mepolizumab 750 mg or
placebo IV every four weeks for 26 weeks.
Administration of mepolizumab resulted in
fewer exacerbations, a longer time to first
exacerbation, and a significant reduction in
prednisone requirements. Subjects treated with
mepolizumab were able to reduce their dose of
prednisone by a mean (±SD) of 83.8 ± 33.4% of
the maximum possible dose compared to
47.7 ± 40.5% in the placebo group (p = 0.04),
but there was no difference in the perhaps more
clinically meaningful final mean dose of
prednisone between the groups. There were no
serious adverse events in the study.
In the first of two large international
multicenter, randomized, double-blinded,
placebo-controlled trials, the Dose Ranging
Efficacy And safety with Mepolizumab in
severe asthma (DREAM) trial [36], Pavord et al.
enrolled 621 participants with severe asthma
with recurrent exacerbations and evidence of
eosinophilic inflammation defined as a sputum
eosinophil count C3%, peripheral blood
eosinophil count C300 cells/lL, exhaled nitric
oxide concentration (FeNo) of at least 50 ppb,
or ‘‘prompt deterioration of asthma control
after a 25% or less reduction in regular
maintenance inhaled or oral corticosteroids.’’
Participants were randomized to one of three
doses of mepolizumab (75, 250, or 750 mg) or
placebo IV every four weeks for 13 infusions.
The investigators found that, over the course of
52 weeks, intravenous mepolizumab reduced
peripheral blood and, to a lesser degree,
sputum eosinophil counts, and reduced the
rate of clinically significant exacerbations at a
similar rate regardless of dose when compared
to placebo. Similar to previous studies [33–35],
there was no difference between the groups in
asthma control questionnaire (ACQ) scores or
FEV1, suggesting that strategies for managing
exacerbations and these other aspects of control
might be considered differently in this
population. A subgroup analysis indicated that
the efficacy of mepolizumab in reducing
exacerbation rates increased with higher
baseline eosinophil counts and number of
exacerbations within the preceding year but
not baseline FeNo, suggesting that careful
phenotyping in patient selection for use of
this agent will be important in future studies.
The broad definition of eosinophilic
inflammation for the entry criteria for this
study may have limited its ability to show
significant change, but the idea of
noninvasive, clinically available markers is
appealing.
The second large randomized, double-blind,
placebo-controlled trial, the Mepolizumab as
Adjunctive Therapy in Patients with Severe
Asthma (MENSA) study [37], evaluated a
similar population of refractory asthma with
recurrent exacerbations, but included the
subcutaneous (SQ) route of administration as
an intervention arm, and tightened the
definition of eosinophilic inflammation to
include only those subjects with peripheral
blood eosinophil counts of at least 150 cells/lL
at screening or 300 cells/lL at some point in the
previous year. Participants were randomized to
mepolizumab administered 75 mg IV or 100 mg
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SQ or placebo every four weeks for 32 weeks.
Both routes of administration had similar
efficacies. When compared to placebo, those
treated with mepolizumab demonstrated an
improvement in lung function, had evidence
of improved asthma control with a lower ACQ-5
score (although less than the minimal clinically
significant change of 0.5 [39]), and had
significant improvement in quality of life
(QOL) as measured by a numerical decrease on
the St. Georges Respiratory Questionnaire
(SGRQ). Mepolizumab reduced overall
exacerbation rates from 1.74 to 0.93
exacerbations per patient year in the IV group
(47% reduction, 95% CI 28–60%; p\0.001) and
0.83 in the SQ group (53% reduction, 95% CI
36–65%; p\0.001). Efficacy was again noted to
be linked with markers of eosinophilic
inflammation, with those subjects with
peripheral blood eosinophil counts of over 500
cells/lL having the greatest reduction in
exacerbations. The most commonly reported
adverse events were injection-site reactions.
This study further supports the notion that,
with careful patient selection, mepolizumab can
be effective in a specific population of patients
with severe eosinophilic asthma.
This early suggestion that mepolizumab
could be useful as a glucocorticoid-sparing
agent [35] was later confirmed by the larger
Steroid Reduction with Mepolizumab Study
(SIRIUS) [41], in which 135 patients with
glucocorticoid-dependent eosinophilic asthma
were randomized to mepolizumab 100 mg SQ or
placebo every four weeks for 20 weeks as an
additive therapy. Similar to MENSA [37], the
SIRIUS investigators defined eosinophilic
asthma as the presence of a peripheral blood
eosinophil level of least 300 cells/lL on initial
screening, or at least 150 cells/lL during the
run-in phase of the trial. Administration of
mepolizumab resulted in a significant reduction
in daily glucocorticoid dose (50% median
reduction from baseline compared to no
reduction in the placebo group, p = 0.007), a
reduced annualized rate of exacerbation (1.44
exacerbations per patient year versus 2.12,
p = 0.04), as well as improvements in the
ACQ-5 and SGRQ. Previous studies [34, 36, 37]
did not demonstrate this improvement in
asthma control with mepolizumab, suggesting
that there may be a greater potential for
symptomatic control in those patients who are
steroid dependent. There was no significant
difference in ability to wean completely off
glucocorticoid therapy, but the trial’s short
length may have limited the ability to
completely assess this or its long-term effect
on exacerbations. The safety profile for
mepolizumab was similar to placebo, but six
(4%) participants in the two study groups
developed non-neutralizing antibodies to
mepolizumab.
Overall, a 2013 meta-analysis of seven
randomized controlled trials comparing
mepolizumab to placebo concluded that
mepolizumab ‘‘appears to be useful for control
of exacerbations and improve asthma-related
quality of life in individuals with persistent
airway eosinophilia’’ [42]. The authors did not
find a significant difference in pooled change in
FEV1 [42], although the analysis was published
prior to the MENSA study, so additional
statistical analysis may be warranted in the
future. The reductions in both peripheral
[33–36, 42] and sputum [34, 35, 42] eosinophil
counts in those receiving mepolizumab were
significant and, given the specificity of
monoclonal-antibody-targeted therapy, is
supportive of the causal relationship between
reduction in eosinophilic inflammation and
rate of exacerbation.
Based on the growing body of literature
[33–37, 41, 42], mepolizumab was approved
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for clinical use in the European Union by the
European Medicines Agency (EMA) on
September 24, 2015 [43], and in the United
States by the Food and Drug Administration
(FDA) on November 4, 2015 [44]. It is approved
as an add-on maintenance treatment of patients
with severe asthma with an eosinophilic
phenotype (peripheral blood eosinophil count
C300 cells/lL or sputum eosinophil count C3%)
aged 12 years and older. The recommended
dose is 100 mg administered by subcutaneous
injection of the thigh, upper arm, or abdomen
every four weeks. There were few serious side
effects reported in clinical trials of
mepolizumab [44]. The most common adverse
effect was headache (19% vs. 18% placebo),
followed by injection site reaction (8% vs. 3%
placebo). Severe hypersensitivity reactions have
been reported in pooled data (7% of those who
received placebo versus 10% who received
mepolizumab), as has herpes zoster infection
(two cases during clinical trials) [44].
RESLIZUMAB
Similar to mepolizumab, reslizumab is a
humanized monoclonal antibody targeted
against IL-5, preventing binding to eosinophil
targets [45]. Several randomized controlled
trials comparing reslizumab to placebo have
been completed. The first enrolled 106 adults
with poorly controlled eosinophilic asthma
defined as C3% eosinophils on induced
sputum and an ACQ-7 score of 1.5 or higher
despite high-dose inhaled corticosteroid
therapy (at least 880 lg fluticasone or
equivalent daily) plus an additional controller
[46]. Over a short 15-week observation period,
there was a trend towards improvement in
mean ACQ-7 score with reslizumab
administration, but this did not reach
statistical significance except in the subgroup
of participants with nasal polyps (p = 0.0119).
Participants who received reslizumab showed
significantly greater improvements in lung
function, including FEV1 and forced vital
capacity (FVC), and reductions in both
peripheral blood (40% reduction) and induced
sputum (95% reduction) eosinophil counts
than those who received placebo. The
improvement in FEV1 was most pronounced in
those subjects with peripheral blood
eosinophils of at least 500 cells/lL or more at
baseline, further highlighting the need to
clearly establish the appropriate phenotype in
which these agents are likely to be effective.
A more recent publication described data
collected from two duplicate multicenter,
randomized, placebo-controlled trials that
included adolescents and adults with
uncontrolled eosinophilic asthma defined by
an ACQ-7 score C1.5 and at least 440 lg
fluticasone or equivalent daily with or without
an additional controller agent and with a
peripheral blood eosinophil count C400 cells/
lL. A total of 953 participants were randomized
to receive either reslizumab 3 mg/kg or placebo
IV every four weeks for one year. In pooled data
from both trials, those who received reslizumab
had a significant improvement in overall
exacerbation rates to 0.84 exacerbations per
patient per year versus 1.81 in the placebo
group (reduction of 54%). Reslizumab
treatment also improved lung function, AQLQ
scores (improvement of 1.08 versus 0.81 in
those who received placebo) and ACQ-7 scores
(reduction of 1.02 versus 0.77 in those who
received placebo) over the 52-week study
period. While reslizumab had a similar effect
on rates of asthma exacerbation as those
reported for mepolizumab in DREAM [36] and
MENSA [37], the improvements in asthma
control and lung function were more notable.
The authors speculate that the higher
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eosinophil threshold of C400 cells/lL for
inclusion in these studies may more accurately
represent airway eosinophilia [47], and may
ultimately better predict which patients will
respond to inhibition of IL-5. With the
exception of two patients who suffered from
anaphylaxis that was believed to be related to
the study medication, adverse events were
similar in the two groups [48].
A confirmatory trial comparing two doses of
reslizumab [49] in patients with poorly
controlled eosinophilic asthma (blood
eosinophils C400 cells/lL) randomized
patients 1:1:1 to 0.3 mg/kg reslizumab, 3 mg/
kg reslizumab, and placebo administered IV
once every four weeks for 16 weeks. Reslizumab
improved lung function, asthma symptoms,
and quality of life when compared to placebo,
but there was no significant difference in
asthma control. The effect was generally
greater at the 3.0 mg/kg dose, without an
increase in adverse events. The improvement
in FEV1 did not correlate with baseline
eosinophil levels of C400 cells/lL [49]. Finally,
Corren et al. evaluated the effect of reslizumab
in a population of adults with inadequately
controlled asthma unselected for eosinophilia
[50]. When compared to placebo, there was no
difference in FEV1, ACQ scores, or rescue inhaler
use between groups. The study was not powered
for detailed subgroup analyses, but in those
participants with a peripheral blood eosinophil
count of C400 cells/lL, there was a significant
improvement in FEV1 (270 mL) compared to
placebo, supporting a blood eosinophil
threshold of C400 cells/lL for clinical use.
Based on the previous body of work
[46, 48–50], reslizumab was approved for use
in the US on March 23, 2016 by the FDA [51]
and the EU on June 23, 2016 by the EMA [52]
for add-on maintenance therapy for severe
asthma in adults aged 18 years or older with
an eosinophilic phenotype. The recommended
dose is 3 mg/kg every four weeks administered
by intravenous infusion over 20–50 min [53].
Anaphylaxis was reported in 0.3% of patients
included in all clinical trials (0% in placebo).
Other adverse effects include oropharyngeal
pain (2.6% vs. 2.2% placebo) and creatine
phosphokinase (CPK) elevation (14% vs. 9%
placebo) [53].
BENRALIZUMAB
Rather than directly binding and inhibiting
IL-5, benralizumab is an investigational
humanized monoclonal antibody that is
directed at a subunit of the IL-5 receptor
(IL-5R) located on eosinophils and basophils
that induces apoptosis [54]. In a small
phase-one trial, intravenous and subcutaneous
benralizumab was shown to effectively decrease
eosinophil counts in both peripheral blood and
sputum, with a trend toward a reduction in
peripheral blood basophil counts compared to
placebo [55]. In a phase two, randomized,
double-blind, placebo-controlled parallel group
study, patients with physician-diagnosed
asthma and at least one exacerbation requiring
urgent care in the preceding 12 months who
presented to the emergency department with an
acute asthma exacerbation were randomized to
either a single dose of benralizumab (0.3 or
1.0 mg/kg) or placebo in addition to usual care
administered at the time of presentation, and
were followed over a 12-week period [56].
Patients were enrolled regardless of peripheral
blood eosinophil levels. There was no difference
between groups in number of exacerbations at
four, 12, or 24 weeks, FEV1, ACQ, or AQLQ
scores. However, pooled analysis found that
benralizumab significantly decreased the rate of
exacerbations when compared to placebo
(p = 0.01). Interestingly, the effect of
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benralizumab was not related to blood
eosinophil count in this study.
A second larger randomized, controlled,
dose-ranging trial enrolled adults with
uncontrolled moderate-to-severe asthma and a
history of recurrent exacerbations to receive
benralizumab over one year at varying doses
[57]. Patients were classified as either
eosinophilic or non-eosinophilic based on an
elevated FeNo ([50 ppb) in combination with a
mathematical algorithm to predict sputum
eosinophils. A significant reduction in annual
exacerbationratewas found inthose subjectswith
an eosinophilic subtype who received 100 mg
benralizumab versus those who received placebo,
although,due to thenatureandgoals of the study,
the authors accepted p\0.169 as significant
rather than the traditional 0.05. Additionally,
there were significant improvements in FEV1 and
ACQ-6 scores in all subjects, regardless of
phenotype, who received benralizumab
compared to those who did not. The activity in
the non-eosinophilic subtype suggests that
benralizumab may be active towards other
IL-5R-expressing cells that contribute to
inflammation [57].
DUPILUMAB
Dupilumab is an investigational humanized
monoclonal antibody against the IL-4 receptor
a-subunit present in two distinct receptors on
lymphocytes (type I receptor) and bone marrow
precursors (type II receptors) [27, 58–60]. The
type I receptor present on lymphocytic
precursors is predominantly responsible for
Th2 cell differentiation and maturation
[27, 60], so inhibition of this differentiation
should reduce the downstream effects of
eosinophilic maturation and activation. A
phase-two randomized controlled trial [61]
enrolled 104 adults with uncontrolled
moderate-to-severe eosinophilic asthma
(peripheral blood eosinophil count C300 cells/
lL or induced sputum eosinophil count C3%).
Participants were randomized to receive
subcutaneous dupilumab 300 mg weekly or
placebo over 12 weeks in addition to inhaled
fluticasone and salmeterol. After 4 weeks,
participants were advised to discontinue
salmeterol and tapered off fluticasone.
Compared to placebo, dupilumab significantly
reduced the number of exacerbations over the
study period (odds ratio 0.08; 95% CI,
0.02–0.28; p\0.001), despite discontinuation
of inhaled corticosteroid and long-acting
beta-agonist therapy. Dupilumab also resulted
in improved lung function and asthma control,
but the short length of the study did not allow
the investigators to duplicate clinical practices
[61]. Although dupilumab effectively reduced
FeNo, serum IgE, and other serum biomarkers
supporting biologic activity, there was no
change in peripheral blood eosinophil counts,
suggesting that reducing eosinophils is not
essential for reducing disease activity.
LEBRIKIZUMAB
Interleukin-13 (IL-13) is a pro-inflammatory
Th2 cytokine secreted by activated T-cells,
eosinophils, natural killer cells, mast cells, and
basophils that acts as a potent stimulator of
mucus production, airway fibrotic changes, and
airway eosinophilia [62]. Serum levels are
elevated in asthma, and this is thought to be a
mechanism of steroid resistance [63]. One of the
mechanisms by which IL-13 induces airway
fibrosis and remodeling is by upregulating the
secretion of periostin [64], which has been
linked as a systemic biomarker specific for
airway eosinophilia [65]. Lebrikizumab is a
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humanized monoclonal antibody that binds to
IL-13, which is under investigation for the
treatment of uncontrolled asthma [66, 67].
Early studies indicate that lebrikizumab may
improve lung function (percent improvement
in baseline FEV1 compared to placebo ranged
from 8.2% to 10.7% in three phase-two trials
[66, 67], although this improvement seems to
be limited to those patients with high baseline
levels of systemic periostin (C50 ng/mL). In
secondary analysis, lebrikizumab was also
shown to decrease FeNo, another marker of
eosinophilic airway inflammation [68].
CONCLUSION
Asthma is a complex chronic inflammatory
condition where patients with severe
eosinophilic airway disease pose a particular
challenge for clinicians. As new biologic
therapies targeted at specific subtypes of
asthma become available, it will be
increasingly important to be able to readily
identify those subgroups of patients who will be
the most likely to respond. Our concept of
asthma phenotyping has evolved from
emphasizing broad clinical classifications to
much more specific biologic characteristics
that can more clearly link the underlying
pathology to the phenotype.
The place of these new biologic agents in our
armamentarium of options for patients with
uncontrolled disease is still being defined, but
the decision to begin such therapies should
carefully weigh the cost of the agent, its safety
profile, and the target population. Standard
asthma therapies should be optimized
according to national guidelines [69, 70], with
attention paid to adherence and control of
comorbid conditions before the addition of
biologics. For currently approved therapies
[44, 53], we recommend consideration prior to
the initiation of chronic systemic steroids to
reduce the risk of exacerbations, or to use them
in add-on therapies as potential steroid-sparing
agents. While strategies for long-term
monitoring of these agents have not been
defined, we recommend a year-long trial for
those patients who tolerate the medications,
with the monitoring of frequency of
exacerbations and healthcare utilization, the
assessment of asthma control with standardized
questionnaires, and the ability to wean systemic
corticosteroids as primary goals.
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